A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18. (April 2012)

• Record Type: Journal Article
• Authors: Goldstone, Stephen E; Vuocolo, Scott
• Is Part Of: Expert review of vaccines. Volume 11:Number 4(2012)
• Page Start: 395
• Page End: 406
• Publication Date: 2012-04
• Subjects: cervical cancer -- HPV -- papillomavirus -- vaccine; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1586/erv.12.20
• Languages: English
• ISSNs: 1476-0584

Abstract

Human papillomavirus infection causes cervical cancer, a significant portion of anal, genital and oropharyngeal cancers, genital warts and recurrent respiratory papillomatosis. In June 2006, a quadrivalent human papillomavirus-6/11/16/18 vaccine (GARDASIL/SILGARD®; Merck, NJ, USA) was licensed in the USA; subsequent approval has been granted in the EU (September 2006). It has since been approved in 121 countries with over 74 million doses distributed globally as of March 2011.